[ad_1] NANJING, China and GAITHERSBURG, Md., Dec. 4, 2025 /PRNewswire/ — TransThera Sciences Inc. (“TransThera”) announced the publication of clinical results from a US-based Phase 2 trial evaluating tinengotinib in patients with Cholangiocarcinoma (CCA) on The […]
Tag: TransThera Sciences (Nanjing) Inc.
INCLUSION OF TINENGOTINIB TABLETS IN THE LIST OF PRODUCTS FOR PRIORITY REVIEW BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
[ad_1] NANJING, China and GAITHERSBURG, Md., Dec. 3, 2025 /PRNewswire/ — TransThera Sciences Nanjing, Inc. (the “TransThera”) announced that Tinengotinib tablets have been included in the List of Products for Priority Review by the Center […]
